A 12 week treatment, multi-centre, randomized, double-blind, parallel-group, active controlled study to assess the efficacy, safety, and tolerability of a fixed dose combination of glycopyrronium (12.5 mcg)/ formoterol fumarate dihydrate (12 mcg) in a dry powder inhaler in comparison with Glenmark AirzTM Glycopyrronium powder for inhalation 50 mcg in subjects with chronic obstructive pulmonary disease
Phase of Trial: Phase III
Latest Information Update: 13 Nov 2019
Price : $35 *
At a glance
- Drugs Formoterol/glycopyrrolate (Primary) ; Glycopyrrolate
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Glenmark Pharmaceuticals Ltd
- 05 Nov 2019 Status changed from recruiting to completed.
- 22 May 2017 Status changed from not yet recruiting to recruiting.
- 09 Mar 2017 New trial record